Patents Represented by Attorney, Agent or Law Firm Kate H. Murashige
  • Patent number: 5780622
    Abstract: A novel 5,15-diarylbenzochlorin-7-one compound having the formula (I) or (II): ##STR1## wherein M is a metal. A novel method for synthesizing the compound of formula (I) comprises the steps of:a. cyclizing a meso-(formylvinyl) 5,15-diarylporphyrin to form a cyclization reaction mixture, andb. oxidizing said reaction mixture to form the 5,15-diarylbenzochlorin-7-one of formula (I).A novel method for synthesizing the compound of formula (II) comprises the cyclizing and oxidizing steps listed above and, either prior to or after the oxidizing step, adding the step of demetallating the compound.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: July 14, 1998
    Assignee: The University of British Columbia
    Inventors: David Dolphin, Ross Boyle
  • Patent number: 5780266
    Abstract: The present invention provides tools which are useful for the diagnosis of an animal's exposure to feline infectious peritonitis virus (FIPV) or susceptibility to FIPV. The diagnostic tools are composed of nucleic acid sequences which encode structural and nonstructural FIPV proteins and antibodies generated against FIPV proteins. The FIPV proteins may also be useful as subunit vaccines.
    Type: Grant
    Filed: March 30, 1994
    Date of Patent: July 14, 1998
    Assignees: Scios Inc., American Home Products Corporation
    Inventors: Beverly Dale, Miles Yamanaka, William M. Acree, Lloyd G. Chavez, Jr.
  • Patent number: 5326752
    Abstract: The compounds are of the formula ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, lower alkyl (1-4C), alkylaryl or one or more additional saccharide residues; R.sup.3 and R.sup.4 are independently H, alkyl (1-6C), aryl or R.sup.3 and R.sup.4, taken together, form a five or six-membered ring optionally containing a hetroatom selected from the group consisting of O, S, and NR.sup.1 ; wherein said five- or six-membered ring may further be substituted by one or more substituents selected from the group consisting of (CHOR.sup.1).sup.m H wherein m is 1-4, OR.sup.1, OOCR.sub.1, NR.sup.1, NCOR.sup.1 and SR.sup.1 ; Y is H, OR.sup.1, OOCR.sup.1, NR.sup.1.sub.2, NCOR.sub.1 or SR.sub.1 ; and X is --CHR.sup.5 (CHOR.sup.1).sub.2 CHR.sup.6 OR.sup.1 wherein R.sup.5 and R.sup.6 are independently H, lower alkyl (1-4C) optionally substituted with one or more R, or result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S and NR.sup.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: July 5, 1994
    Assignee: Glycomed Incorporated
    Inventors: Mina Nashed, Falguni Asgupta, Saeed Abbas, John Musser, Darwin Asa
  • Patent number: 5288721
    Abstract: Compounds of the formula ##STR1## including the resolved enantiomers and/or diastereomers and mixtures thereof wherein each of one or two R is independently ##STR2## wherein n is 1-16 and R' is H or alkyl(1-4C); and wherein each remaining R is independently H, alkyl(1-6C), alkenyl(1-6C) or benzyl; an wherein said alkyl or alkenyl may be substituted by a hydroxyl, halo, or dimethylamino group, and/or interrupted by an oxygen atom, are useful in modulating the effects of internal and external stimuli on cells by reversing the effects of these stimuli on the short-term secondary messenger pathways. In particular, the compounds lower elevated levels of unsaturated, non-arachidonate phosphatidic acid (PA) and diacylglycerol (DAG) derived from said PA within seconds of the primary stimulus and their contact with said cells. The modulatory effect depends on the nature of the target cell and the stimulus applied.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: February 22, 1994
    Assignee: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, David Porubek, Glenn C. Rice, Paul Woodson
  • Patent number: 5280016
    Abstract: A non-anticoagulant (NAC) form of heparin which shows antiproliferative activity with respect to smooth muscle cells is useful in the prevention of restenosis and other conditions benefited by antiproliferative activity with respect to smooth muscle cells. This NAC form of heparin is prepared by oxidizing heparin/heparan sulfate to a desired level with periodate followed by reduction of the resulting aldehyde groups; all under conditions which prevent depolymerization of the heparin.
    Type: Grant
    Filed: September 3, 1991
    Date of Patent: January 18, 1994
    Assignee: Glycomed Incorporated
    Inventors: H. Edward Conrad, Yuchuan Guo
  • Patent number: 5278049
    Abstract: DNA segments encoding two slightly different protease nexin I forms (PN-I.alpha. and PN-I.beta.) are cloned and expressed to provide practical quantities of PN-I for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.
    Type: Grant
    Filed: March 13, 1987
    Date of Patent: January 11, 1994
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Joffre B. Baker, Randy W. Scott
  • Patent number: 5239078
    Abstract: Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;n is 0, 1 or 2;m is 0 or 1; andx is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); orX is an amino acid residue or amide thereof; orX is the residue of a cyclic amine or heterocyclic amine;Y is selected from the group consisting of R.sup.7 ONR.sup.6 CONR.sup.6 -, R.sup.6.sub.2 NCONOR.sup.7 -, and R.sup.6 CONOR.sup.7 -, wherein each R.sup.6 is independently H or lower alkyl (1-4C); R.sup.7 is lower alkyl (1-4C) or an acyl group; andwherein --CONR.sup.3 -- is optionally in modified isoteric form are inhibitors of matrix metalloproteases.
    Type: Grant
    Filed: August 20, 1991
    Date of Patent: August 24, 1993
    Assignee: Glycomed Incorporated
    Inventors: Richard E. Galardy, Damian Grobelny, John H. Musser
  • Patent number: 5234911
    Abstract: A substance is prepared having interleukin-8 inhibiting activity by extracting psoriatic scales and separating the extract on several successive HPLC columns, using an assay for IL-8i activity based on the inhibition of myeloperoxidase release and/or of the neutrophil chemotaxis of a reference sample.The substance is suitable for the preparation of anti-inflammatory medicines.
    Type: Grant
    Filed: January 16, 1991
    Date of Patent: August 10, 1993
    Assignee: Gist-brocades, N.V.
    Inventors: Enno Christophers, Jens-Michael Schroder
  • Patent number: 5206163
    Abstract: The nucleotide sequence of the genome for bovine diarrhea virus (BDV) is disclosed. The sequence permits design and construction of vaccines effective against BDV.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: April 27, 1993
    Assignee: Chiron Corporation
    Inventors: Andre Renard, Dino Dina, Joseph Martial
  • Patent number: 5189178
    Abstract: Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;n is 0, 1 or 2;m is 0 or 1; andX is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); orX is an amino acid residue or amide thereof; orX is the residue of a cyclic amine or heterocyclic amine;wherein R.sup.6 is H or lower alkyl (1-4C) and R.sup.7 is H, lower alkyl (1-4C) or an acyl group, and wherein --CONR.sup.3 -- is optionally in modified isosteric formare useful for treating conditions which are characterized by unwanted matrix metalloprotease activities.
    Type: Grant
    Filed: August 20, 1991
    Date of Patent: February 23, 1993
    Inventors: Richard E. Galardy, Damian Grobelny
  • Patent number: 5145956
    Abstract: Separation of anionic oligosaccharides on a preparative scale with high resolution can be achieved by anionic exchange chromatography using PEI-derivatized supports.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: September 8, 1992
    Assignee: Glycomed Incorporated
    Inventors: Lun H. Lam, David Tyrrell
  • Patent number: 5087636
    Abstract: A method to prepare bone marrow or other hemopoietic cells free of malignant cells for autologous transplants is described. The mononuclear cells from the marrow are treated with a green porphyrin (Gp) to effect the uptake of said Gp by malignant cells selectively, and then irradiated with a wavelength of light absorbed by said Gp to effect the destruction of the malignant cells. The purged marrow cells can then be used for autologous transplantation.
    Type: Grant
    Filed: February 20, 1990
    Date of Patent: February 11, 1992
    Assignee: University of British Columbia
    Inventors: Catriona Jamieson, Julia G. Levy
  • Patent number: 5059535
    Abstract: Specific sialyl transferases (ST) are important enzymes in the manufacture of carbohydrate moieties useful for pharmacological purposes and for diagnostic and clinical procedures. The invention offers simplified methods to isolate highly specific forms of these ST enzymes by taking advantage of the affinity of the ST for its acceptor substrate in the presence of the sialyl-CMP analogs, such as CDP. Specifically exemplified are isolation of the alpha 2,3-ST, specific for Le.sup.c or LacNAc, and alpha 2,6-ST specific for LacNAc.
    Type: Grant
    Filed: April 12, 1989
    Date of Patent: October 22, 1991
    Assignee: Chembiomed, Ltd.
    Inventors: M. Abdul Mazid, Mohammed A. Kashem
  • Patent number: 5013662
    Abstract: Method of obtaining N-terminal methionine-free proteins are described. The methods employ a novel enzyme, E. coli methionine aminopeptidase either in vitro or in vivo. For in vivo application, plasmid-borne DNA encoding the peptidase is transformed into a bacterial host which produces the desired protein.
    Type: Grant
    Filed: October 7, 1988
    Date of Patent: May 7, 1991
    Assignee: Cetus Corporation
    Inventors: Arie Ben-Bassat, Keith A. Bauer, Shing Chang, Sheng-Yung Chang
  • Patent number: 4959314
    Abstract: Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
    Type: Grant
    Filed: February 7, 1985
    Date of Patent: September 25, 1990
    Assignee: Cetus Corporation
    Inventors: David F. Mark, Leo S. Lin, Shi-da Yu Lu, Alice M. Wang
  • Patent number: 4950740
    Abstract: Recombinant diphtheria toxin A fragment muteins which are enzymatically inactive but immunologically crossreactive with diphtheria toxin are disclosed. Intermediates and methods for preparing such proteins using recombinant techniques are also described.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: August 21, 1990
    Assignee: Cetus Corporation
    Inventors: Lawrence Greenfield, Anne W. Emerick, Walter J. Laird
  • Patent number: 4939093
    Abstract: DNA sequences and recombinant DNA molecules which encode human IL-2 IL-2 like polypeptides, hosts transformed with vectors carrying the DNA sequences as inserts, methods for their production and therapeutic formulations utilizing the IL-2 and IL-2 like polypeptides are provided.
    Type: Grant
    Filed: August 23, 1988
    Date of Patent: July 3, 1990
    Assignee: Cetus Corporation
    Inventors: Michael P. McGrogan, Ernest S. Kawasaki, Michael V. Doyle, David F. Mark
  • Patent number: 4894443
    Abstract: A novel class of polypeptides of the general formula (F-(Pro).sub.n).sub.m F, wherein F represents a flexible amino acid sequence wherein each amino acid is individually selected from the group consisting of serine, glycine, and threonine, and n is an integer from 4-8 inclusive and m is an integer from 1-4 inclusive, is disclosed. Thses polypeptides are useful in the construction of conjugates between antibodies and peptide toxins. The preparation of such conjugate toxins by linking antibodies to toxin/spacer composites prepared by recombinant techniques is also disclosed.
    Type: Grant
    Filed: September 7, 1984
    Date of Patent: January 16, 1990
    Assignee: Cetus Corporation
    Inventors: Lawrence I. Greenfield, Donald A. Kaplan, Danute E. Nitecki
  • Patent number: 4870017
    Abstract: Methods of obtaining N-terminal methionine-free proteins are described. The methods employ a novel enzyme, E. coli methionine aminopeptidase either in vitro or in vivo. For in vivo application, plasmid-borne DNA encoding the peptidase is transformed into a bacterial host which produces the desired protein.
    Type: Grant
    Filed: September 20, 1985
    Date of Patent: September 26, 1989
    Assignee: Cetus Corporation
    Inventors: Arie Ben-Bassat, Keith A. Bauer, Shing Chang, Sheng-Yung Chang
  • Patent number: 4870013
    Abstract: Expression vectors containing coding sequences under the control of SV40 early and RSV promoters are disclosed as useful in producing proteins in saccharomyces yeasts. Construction of such vectors, and their use in yeast transformations are described.
    Type: Grant
    Filed: May 18, 1988
    Date of Patent: September 26, 1989
    Assignee: Cetus Corporation
    Inventors: David H. Gelfand, Frances C. Lawyer, Susanne Stoffel